Compare InMode Ltd (INMD) vs Johnson & Johnson (JNJ) Price & Performance

InMode (INMD) trades at $14.21, up 1.43% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with a P/E of 11.63, gross margins of 76.52%, and consistent profitability. Recent Q2 2026 earnings beat expectations with $95.6M revenue, while facing shareholder activism from Steel Partners' $16.75 per share acquisition offer.

Investment outlook remains cautious with analyst consensus divided (45% Buy, 55% Hold) amid cyclical industry softness. Key opportunities include international growth and new product launches like Morpheus8 Cool, while risks involve US sales declines and capital allocation concerns. The stock presents value characteristics but requires monitoring of management's strategic response to acquisition pressure.

Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).

JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.